Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Advanced Breast Cancer.

Trial Profile

Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Advanced Breast Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Mar 2015

At a glance

  • Drugs Dasatinib (Primary) ; Capecitabine
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 31 Dec 2013 Protocol has been amended to add dasatinib 100mg, once per day.
    • 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top